Summit Therapeutics (LON:SUMM) issued its quarterly earnings data on Wednesday. The company reported GBX (3) (($0.04)) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of GBX (10.10) (($0.14)) by GBX 7.10 ($0.10), Bloomberg Earnings reports. The company had revenue of £173 million for the quarter.

Shares of Summit Therapeutics (SUMM) opened at GBX 180 ($2.42) on Wednesday. Summit Therapeutics has a 1-year low of GBX 138.14 ($1.86) and a 1-year high of GBX 269.70 ($3.63).

SUMM has been the topic of a number of recent research reports. N+1 Singer reissued a “corporate” rating on shares of Summit Therapeutics in a report on Tuesday, November 7th. reissued a “corporate” rating on shares of Summit Therapeutics in a report on Tuesday, November 7th.

ILLEGAL ACTIVITY NOTICE: “Summit Therapeutics (SUMM) Issues Earnings Results, Beats Expectations By $7.10 EPS” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at

About Summit Therapeutics

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with's FREE daily email newsletter.